Tokai Pharmaceuticals (United States)

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber et al. · Journal of Clinical Oncology · 2017 · 472 citations

Medicine, Oncology, Pharmacology +17

Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer

Mary-Ellen Taplin, Emmanuel S. Antonarakis, Karen J. Ferrante et al. · European Urology · 2019 · 66 citations

Medicine, Oncology, Pharmacology +17

Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC).

Bruce Montgomery, Mario A. Eisenberger, Matthew B. Rettig et al. · Journal of Clinical Oncology · 2012 · 35 citations

Medicine, Oncology, Pharmacology +17

The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival

Urszula L. McClurg, Mahsa Azizyan, Daniel T. Dransfield et al. · Oncotarget · 2018 · 33 citations · Full text

Medicine, Biochemistry, Oncology +17

Novel, orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium

William H. Catherino, Minnie Malik, Paul H. Driggers et al. · The Journal of Steroid Biochemistry and Molecular Biology · 2010 · 31 citations

Medicine, Gynecology, Pharmacology +12